Cancer Therapeutics, led by researchers from Ca’ Foscari University in Venezia and CRO Aviano (Italy), is one of the supported research teams in the first S3E Start Programme.
The team behind Cancer Therapeutics is introducing a revolutionary technology that presents a ground-breaking system designed for the treatment of solid tumour ovarian cancer, known as Copper Nitroprusside (CuNP).
Ovarian cancer ranks as the 7th most aggressive cancer in women globally, with a survival rate of less than 30%. In the year 2023, there were 314,959 newly diagnosed cases of ovarian cancer, resulting in 207,253 reported deaths. Among the various types of ovarian cancer, High Grade Serous Ovarian Cancer (HGSOC) is particularly aggressive, accounting for approximately 70% of ovarian carcinoma cases and exhibiting high mortality rates.
Traditionally, chemotherapy has been employed as the primary treatment for ovarian cancer. However, nearly 50% of patients develop resistance to the existing therapies, necessitating costly second-line treatments. This technology, named Copper Nitroprusside (CuNP), overcomes the limitations of current therapeutic approaches. It addresses issues such as cost reduction, biocompatibility, and the destruction of dense tumour matrices, which pose significant challenges in the field of cancer medicine. Moreover, this technology overcomes chemotherapy-related problems by simultaneously supplying multiple Reactive Oxygen Species (ROS) without the need for external stimuli. This unique system initiates the Fenton reaction with exceptional efficiency. Notably, these CDT agents possess the ability to generate multiple ROS and nitrogen-based reactive species at the tumour site, further enhancing their therapeutic effectiveness.
This remarkable enhancement obviates the need for additional drugs, external stimuli, or delivery systems. Significantly, no comparable system capable of generating dual ROS in cancer therapy with such high therapeutic efficacy and minimal side effects has been developed until now. Cancer Therapeutics’ product offers an effective approach to combat and overcome ovarian cancer, providing hope for patients in need of a more advanced treatment option.
Learn more about Cancer Therapeutics by watching the pitch done by researcher Kanwal Asif during the Start Open Day on 20th July 2023.
Would you like to get in touch with them? Let us know! Email us at info@south3e.eu